Study identifier:D5896C00022
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 52-week, randomised, double-blind, parallel-group, multi-centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma
asthma
Phase 3
No
Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
All
742
Interventional
12 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
Location
Location
Highpoint, NC, United States
Location
Union, SC, United States
Location
Richmond, VA, United States
Location
Metairie, LA, United States
Location
Spartanburg, SC, United States
Location
Upland, PA, United States
Location
Blackwood, NJ, United States
Location
Columbia, SC, United States
Arms | Assigned Interventions |
---|---|
Experimental: Symbicort Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID) | Drug: Budesonide/formoterol (SYMBICORT) pMDI Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID) |
Experimental: Budesonide Budesonide HFA pMDI 160 ug x 2 actuations BID | Drug: Budesonide HFA pMDI Budesonide HFA pMDI 160 ug x 2 actuations BID |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.